The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Following on the heels of the FDA's December 7, safety warning about Pradaxa, a just released study shows even more risks associated with the anti-clotting drug.

Recent findings by researchers at the renowned Cleveland Clinic show patients taking Pradaxa have a 33% higher risk of heart attack or severe symptoms of heart disease than do patients taking warfarin.

The findings are based on data from 30,514 patients in 7 clinical trials. Reaserchers concluded the risk of heart attack or acute coronary syndrome is increased by one-third when compared with warfarin. (Warfarin is most commonly known as the brand name Coumadin)

Acute coronary syndrome (acute symptoms of serious heart disease) is usually caused by the rupture of a plaque in the heart artery.

As we noted in a previous blog, this is not the first safety warning issued for Pradaxa. The FDA is investigating unusually large reports of serious bleeding associated with the drug, Japan and Australia have also issued safety warnings, and in fact, Boehringer Ingelheim Pharmaceuticals is acknowledging 260 deaths associated with the use of Pradaxa.

Given the sheer number of patients currently taking Pradaxa, the number of deaths or serious side effects is likely to climb as investigations into the drug continue.

If you or a loved one taking Pradaxa has experienced side effects such as:

Severe bleeding or you bleeding that cannot be controlled

Blood in urine or stools

Bruises that occur easily or appear without a cause

Coughing up or vomiting blood

If so, contact your doctor immediately to discuss your medical options. You may also have a claim against the makers of Pradaxa, Boehringer Ingelheim Pharmaceuticals, and we would be happy to discuss it with you at no charge.

Comments are closed.

Of Interest